StockStory.org on MSN
3 reasons to sell JCI and 1 stock to buy instead
Johnson Controls has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 10.3% to $115.26 per share while the index has ...
Investors in Johnson Controls International plc (Symbol: JCI) saw new options begin trading today, for the December 2026 expiration. One of the key inputs that goes into the price an option buyer is ...
Zacks Investment Research on MSN
Johnson Controls exhibits strong prospects despite persisting headwinds
Johnson Controls International plc JCI is benefiting from solid momentum across all segments. Increase in demand for heating, ...
Johnson Controls International plc (NYSE:JCI) is one of the best industrial stocks to buy. On November 7, Goldman Sachs maintained a Buy rating on JCI following its fiscal Q4 earnings topping ...
Johnson Controls Intl (NYSE:JCI) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.03%. Currently, Johnson Controls Intl has a ...
Johnson Controls International (JCI) shares rose 4.3% in premarket trading Wednesday after the smart-building technology company reported fiscal fourth-quarter results that topped Wall Street’s ...
CORK, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Johnson Controls (JCI) International plc (NYSE: JCI), the global leader in smart, healthy and sustainable buildings, has approved ...
Fintel reports that on November 6, 2025, Mizuho maintained coverage of Johnson Controls International (NYSE:JCI) with a Neutral recommendation. As of October 30, 2025, the average one-year price ...
Johnson Controls International (JCI) has quietly rewarded patient shareholders, with the stock climbing about 51% year to date and roughly 50% over the past year, outpacing many industrial peers. See ...
Shares of AbbVie have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (+27.1% vs. +11.7%). The Zacks analyst believes that several new drugs in AbbVie’s portfolio have the ...
A significant insider transaction involving the exercise of company stock options was reported on December 3, by Marc Vandiepenbeeck, EVP and CFO at Johnson Controls Intl (NYSE:JCI), as per the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results